169 related articles for article (PubMed ID: 15158969)
1. Polymeric anticancer drugs with pH-controlled activation.
Ulbrich K; Etrych T; Chytil P; Pechar M; Jelinkova M; Rihova B
Int J Pharm; 2004 Jun; 277(1-2):63-72. PubMed ID: 15158969
[TBL] [Abstract][Full Text] [Related]
2. Star-shaped immunoglobulin-containing HPMA-based conjugates with doxorubicin for cancer therapy.
Etrych T; Mrkvan T; Ríhová B; Ulbrich K
J Control Release; 2007 Sep; 122(1):31-8. PubMed ID: 17631976
[TBL] [Abstract][Full Text] [Related]
3. HPMA copolymers with pH-controlled release of doxorubicin: in vitro cytotoxicity and in vivo antitumor activity.
Ulbrich K; Etrych T; Chytil P; Jelínková M; Ríhová B
J Control Release; 2003 Feb; 87(1-3):33-47. PubMed ID: 12618021
[TBL] [Abstract][Full Text] [Related]
4. Antibody-targeted polymer-doxorubicin conjugates with pH-controlled activation.
Ulbrich K; Etrych T; Chytil P; Jelínková M; Ríhová B
J Drug Target; 2004; 12(8):477-89. PubMed ID: 15621674
[TBL] [Abstract][Full Text] [Related]
5. Conjugates of doxorubicin with graft HPMA copolymers for passive tumor targeting.
Etrych T; Chytil P; Mrkvan T; Sírová M; Ríhová B; Ulbrich K
J Control Release; 2008 Dec; 132(3):184-92. PubMed ID: 18534705
[TBL] [Abstract][Full Text] [Related]
6. Poly(ethylene glycol)-poly(ester-carbonate) block copolymers carrying PEG-peptidyl-doxorubicin pendant side chains: synthesis and evaluation as anticancer conjugates.
Andersson L; Davies J; Duncan R; Ferruti P; Ford J; Kneller S; Mendichi R; Pasut G; Schiavon O; Summerford C; Tirk A; Veronese FM; Vincenzi V; Wu G
Biomacromolecules; 2005; 6(2):914-26. PubMed ID: 15762660
[TBL] [Abstract][Full Text] [Related]
7. Polymer conjugates of the highly potent cytostatic drug 2-pyrrolinodoxorubicin.
Studenovsky M; Ulbrich K; Ibrahimova M; Rihova B
Eur J Pharm Sci; 2011 Jan; 42(1-2):156-63. PubMed ID: 21075206
[TBL] [Abstract][Full Text] [Related]
8. Bio-functional micelles self-assembled from a folate-conjugated block copolymer for targeted intracellular delivery of anticancer drugs.
Liu SQ; Wiradharma N; Gao SJ; Tong YW; Yang YY
Biomaterials; 2007 Mar; 28(7):1423-33. PubMed ID: 17141308
[TBL] [Abstract][Full Text] [Related]
9. PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity.
Veronese FM; Schiavon O; Pasut G; Mendichi R; Andersson L; Tsirk A; Ford J; Wu G; Kneller S; Davies J; Duncan R
Bioconjug Chem; 2005; 16(4):775-84. PubMed ID: 16029018
[TBL] [Abstract][Full Text] [Related]
10. Biological evaluation of polymeric micelles with covalently bound doxorubicin.
Vetvicka D; Hruby M; Hovorka O; Etrych T; Vetrik M; Kovar L; Kovar M; Ulbrich K; Rihova B
Bioconjug Chem; 2009 Nov; 20(11):2090-7. PubMed ID: 19835372
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of PK1 and doxorubicin in experimental colon tumor models with differing responses to PK1.
Loadman PM; Bibby MC; Double JA; Al-Shakhaa WM; Duncan R
Clin Cancer Res; 1999 Nov; 5(11):3682-8. PubMed ID: 10589787
[TBL] [Abstract][Full Text] [Related]
12. Poly(amidoamine) conjugates containing doxorubicin bound via an acid-sensitive linker.
Lavignac N; Nicholls JL; Ferruti P; Duncan R
Macromol Biosci; 2009 May; 9(5):480-7. PubMed ID: 19016501
[TBL] [Abstract][Full Text] [Related]
13. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects.
Garde SV; Forté AJ; Ge M; Lepekhin EA; Panchal CJ; Rabbani SA; Wu JJ
Anticancer Drugs; 2007 Nov; 18(10):1189-200. PubMed ID: 17893520
[TBL] [Abstract][Full Text] [Related]
14. MMPs-specific PEGylated peptide-DOX conjugate micelles that can contain free doxorubicin.
Lee GY; Park K; Kim SY; Byun Y
Eur J Pharm Biopharm; 2007 Nov; 67(3):646-54. PubMed ID: 17499491
[TBL] [Abstract][Full Text] [Related]
15. In vivo antitumor activity of the folate-conjugated pH-sensitive polymeric micelle selectively releasing adriamycin in the intracellular acidic compartments.
Bae Y; Nishiyama N; Kataoka K
Bioconjug Chem; 2007; 18(4):1131-9. PubMed ID: 17488066
[TBL] [Abstract][Full Text] [Related]
16. New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties.
Etrych T; Jelínková M; Ríhová B; Ulbrich K
J Control Release; 2001 May; 73(1):89-102. PubMed ID: 11337062
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin-polyphosphazene conjugate hydrogels for locally controlled delivery of cancer therapeutics.
Chun C; Lee SM; Kim CW; Hong KY; Kim SY; Yang HK; Song SC
Biomaterials; 2009 Sep; 30(27):4752-62. PubMed ID: 19520429
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin-polymer conjugates: further demonstration of the concept of enhanced permeability and retention.
Muggia FM
Clin Cancer Res; 1999 Jan; 5(1):7-8. PubMed ID: 9918196
[No Abstract] [Full Text] [Related]
19. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer.
Wong HL; Bendayan R; Rauth AM; Wu XY
J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy based on HPMA copolymer conjugates with pH-controlled release of doxorubicin triggers anti-tumor immunity.
Mrkvan T; Sirova M; Etrych T; Chytil P; Strohalm J; Plocova D; Ulbrich K; Rihova B
J Control Release; 2005 Dec; 110(1):119-29. PubMed ID: 16269198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
